Represents the additional milestone payments to be made under the license agreement.

No definition available.

Name:	incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of the milestone payment made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.

+ References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - MacroGenics (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended		57 Months Ended
	Jul. 31, 2022	Oct. 31, 2017	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
License agreements
Research and development			$ 347,196	$ 343,511	$ 700,569	$ 650,407
MacroGenics
License agreements
Research and development			14,800	$ 17,600	28,300	$ 31,200
MacroGenics \| Accrued and other liabilities
License agreements
Accrued and other liabilities			$ 600		$ 600		$ 600	$ 700
MacroGenics \| Minimum
License agreements
Royalty payments on future global net sales (as a percent)		15.00%
MacroGenics \| Maximum
License agreements
Royalty payments on future global net sales (as a percent)		24.00%
MacroGenics \| Development and Regulatory Milestones \| Maximum
License agreements
Additional milestone payments under the license agreement		$ 365,000
MacroGenics \| Development and Regulatory Milestones \| Maximum \| Subsequent Event [Member]
License agreements
Additional milestone payments under the license agreement	$ 335,000
MacroGenics \| Development Milestones
License agreements
Milestone payment made under license agreement							$ 70,000
MacroGenics \| Development Milestones \| Subsequent Event [Member]
License agreements
Milestone payment made under license agreement	$ 30,000
MacroGenics \| Commercialization Milestones \| Maximum
License agreements
Additional milestone payments under the license agreement		$ 330,000